

Haematologica  
HAEMATOL/2018/208876  
Version 3

Evidence for prevention of renal dysfunction associated with primary  
myelofibrosis by cytoreductive therapy

Yasutaka Fukuda, Marito Araki, Kouji Yamamoto, Soji Morishita,  
Tadaaki Inano, Kyohei Misawa, Tomonori Ochiai, Yoko Edahiro, Misa  
Imai, Hajime Yasuda, Akihiko Gotoh, Akimichi Ohsaka, and Norio  
Komatsu

Disclosures: NK received a research grant from FUJIFILM Wako Pure Chemical, honoraria from Takeda Pharmaceutical, Novartis Pharma, Celgene, Otsuka Pharmaceutical, AbbVie and JT, and scholarship grants from Otsuka Pharmaceutical, Chugai Pharmaceutical, Kyowa Hakko Kirin, Takeda Pharmaceutical, Novartis Pharma, Pfizer, Sumitomo Dainippon Pharma, and Bristol-Myers Squibb. AO received a research grant from Cepheid and scholarship grants from Novartis Pharma, Pfizer, SRL, and Japan Blood Products Organization. Other authors declare no competing financial interests. The sponsors had no role in study design, data collection, analysis and interpretation of the report.

Contributions: YF performed research and wrote the initial draft of the manuscript. MA contributed to interpretation of data and assisted in the preparation of the manuscript. KY performed data analysis. SM, TI, KM, TO, YE have contributed to data collection. MI, HY, AG, AO, NK supervised the study.